PharmaIntellect - Pharma Deals

Servier in licensing pact with SIMM for the development in China of lucitanib

2013-09-18T06:58:00.002-07:00

Servier has signed an agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM) for the development in China of lucitanib, a promising targeted anti-tumor drug with antiangiogenic effects. The drug has demonstrated impressive efficacy in PhI/PhII trials in metastatic breast cancer patients. In heavily pre-treated breast cancer patients,

Azaya therapeutics outlicenses rights to liposomal docetaxel (AT1123) to Beijing’s CANbridge Lifescience

2013-09-16T05:40:00.003-07:00

CANbridge Life Sciences, a Beijing in-licensing firm, has secured the China rights to a cancer drug from Azaya Therapeutics of San Antonio, TX. The drug, ATI-1123, is a liposomal formulation of docetaxel that has completed a Phase I trial in the US. CANbridge will fund clinical development of ATI-1123 for non-small cell lung cancer in China, Taiwan and Korea, collaborating with Azaya on

AstraZeneca and Merck & Co Inc enter into worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775)

2013-09-11T00:25:00.000-07:00

AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775). MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

Eddingpharm inlicenses China rights to Entinostat from Syndax Pharma

2013-09-10T02:16:00.000-07:00

Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions. Financial details are

Otsuka to acquire Astex Pharmaceuticals for $886m

2013-09-09T23:33:00.001-07:00

Otsuka Holdings will buy Astex for a total of around $886m at $8.50/share, a 27% premium to the 3 September closing price. The acquisition allows Otsuka to: 1) strengthen its drug-discovery research using Astex’ fragment-based drug discovery technology; 2) expand its development pipeline, including five anticancer compounds; and 3) receive royalty revenues for Dacogen to treat myelodysplastic

Recordati to acquire Spanish pharmaceutical company Laboratorios Casen Fleet

2013-09-09T23:20:00.000-07:00

Recordati will acquire 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza. The value of the transaction (enterprise value) is of € 93 million and will be funded from existing liquidity. The transaction values Laboratorios Casen Fleet at 2 times sales. The closing of the

Japan based Suntory Beverage and Food limited to buy GSK 's nutritional drinks brand Lucozade and Ribena for £1.35 billion

2013-09-09T00:43:00.000-07:00

GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd (SBF), the Japanese consumer goods company, for £1.35 billion in cash. It is expected that the transaction will be completed by the end of the year, subject to regulatory approvals. GSK’s Consumer

Novartis announces an exclusive global licensing and research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space

2013-09-05T22:27:00.001-07:00

Novartis today announced that it has entered into an exclusive global licensing and research collaboration agreement with Regenerex LLC, a biopharmaceutical company based in Louisville, Kentucky, for use of the company's novel Facilitating Cell Therapy (FCRx) platform. The hematopoietic stem cell-based FCRx platform has been investigated in kidney transplantation to induce stable

Neurodyn acquires all assets related to Galantos preclinical asset Memogain - A prodrug of Galantamine intended for the treatment of Alzheimer

2013-09-05T05:55:00.000-07:00

Neurodyn Inc. has acquired from Galantos Pharma GmbH, Mainz, Germany (galantos.com) all assets related to their Alzheimer’s prescription drug candidate – Memogain®. Memogain® is a prodrug of Galantamine and has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The pro-drug greatly enhances

Endo acquires Specialty Generics Company Boca Pharmacal

2013-09-05T03:06:00.000-07:00

Endo announced the acquisition of Boca Pharmacal, a specialty generics company that focuses on commercializing and developing products that include tablets and capsules, semisolids, solutions and suspensions. Endo will pay $225m in cash for Boca. Transaction Valuation Endo is acquiring Boca Pharmacal for $225M in cash and the transaction is expected to be accretive to 2013 EPS. &

Axxess Pharma Inc to Acquire Canadian OTC Healthcare Company

2013-09-03T23:19:00.001-07:00

Axxess Pharma Inc a specialty pharmaceutical and nutritional supplements company, today announced an Agreement in Principle to acquire a leading Canadian OTC healthcare company. Upon completion of the acquisition, the company will bring current sales and a valuable IP portfolio to Axxess Pharma. The Canadian Corporation, based in Toronto, has an attractive IP portfolio including a

Meda to acquire a respiratory company in the US

2013-09-03T22:57:00.001-07:00

Meda is to acquire the US development company Acton Pharmaceuticals, Inc. (“Acton”) for upto $200m. Meda will pay $135m upfront, while the rest would be contingent on milestones (sales and regulatory). The primary product in Acton portfolio is Aerospan, which is an inhaler for the treatment of asthma that contains the active substance Flunisolide. The product is approved by the FDA

Micurx raises $25m to fund U.S. Development of MRX-I Next-Generation Antibiotic

2013-08-27T06:54:00.000-07:00